Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma
Robert Montal, Daniela Sia, Carla Montironi, et al.
Journal of Hepatology (2020) Vol. 73, Iss. 2, pp. 315-327
Open Access | Times Cited: 219

Showing 1-25 of 219 citing articles:

Immunotherapies for hepatocellular carcinoma
Josep M. Llovet, Florian Castet, Mathias Heikenwälder, et al.
Nature Reviews Clinical Oncology (2021) Vol. 19, Iss. 3, pp. 151-172
Closed Access | Times Cited: 1170
Cholangiocarcinoma
Paul J. Brindley, Melinda Bachini, Sumera I. Ilyas, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 503
Cholangiocarcinoma
Samantha Sarcognato, Diana Sacchi, Matteo Fassan, et al.
Pathologica (2021) Vol. 113, Iss. 3, pp. 158-169
Open Access | Times Cited: 125
Practical considerations in screening for genetic alterations in cholangiocarcinoma
Tanios Bekaii‐Saab, John Bridgewater, Nicola Normanno
Annals of Oncology (2021) Vol. 32, Iss. 9, pp. 1111-1126
Open Access | Times Cited: 108
Cholangiocarcinoma — novel biological insights and therapeutic strategies
Sumera I. Ilyas, Silvia Affò, Lipika Goyal, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 7, pp. 470-486
Open Access | Times Cited: 92
Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications
Miguel A. Martín-Serrano, Benjamin Kepecs, Miguel Torres‐Martín, et al.
Gut (2022) Vol. 72, Iss. 4, pp. 736-748
Open Access | Times Cited: 90
Immunology and immunotherapy of cholangiocarcinoma
Tim F. Greten, Robert F. Schwabe, Nabeel Bardeesy, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 6, pp. 349-365
Closed Access | Times Cited: 90
Cholangiocarcinoma: Recent Advances in Molecular Pathobiology and Therapeutic Approaches
Divya Khosla, Shagun Misra, Pek Lim Chu, et al.
Cancers (2024) Vol. 16, Iss. 4, pp. 801-801
Open Access | Times Cited: 17
Digestive cancers: mechanisms, therapeutics and management
Tianzuo Zhan, Johannes Betge, Nadine Schulte, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 2
Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death‐Ligand 1 Blockade Responses
Jihoon G. Yoon, Min Hwan Kim, Mi Jang, et al.
Hepatology (2021) Vol. 74, Iss. 4, pp. 1914-1931
Closed Access | Times Cited: 68
Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures
María Arechederra, María Rullán, Irene Amat, et al.
Gut (2021) Vol. 71, Iss. 6, pp. 1141-1151
Open Access | Times Cited: 62
Cell of origin in biliary tract cancers and clinical implications
Agrin Moeini, Philipp K. Haber, Daniela Sia
JHEP Reports (2021) Vol. 3, Iss. 2, pp. 100226-100226
Open Access | Times Cited: 59
WDR5 facilitates EMT and metastasis of CCA by increasing HIF-1α accumulation in Myc-dependent and independent pathways
Tianli Chen, Kangshuai Li, Zengli Liu, et al.
Molecular Therapy (2021) Vol. 29, Iss. 6, pp. 2134-2150
Open Access | Times Cited: 58
ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma
Helena Verdaguer, Tamara Saurí, Daniel Acosta, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 8, pp. 1662-1671
Open Access | Times Cited: 46
Multimodule characterization of immune subgroups in intrahepatic cholangiocarcinoma reveals distinct therapeutic vulnerabilities
Jian Lin, Yuting Dai, Chen Sang, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 7, pp. e004892-e004892
Open Access | Times Cited: 46
The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers
Yaodong Zhang, Zijian Ma, Changxian Li, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 43
Rational development of combination therapies for biliary tract cancers
James J. Harding, Danny N. Khalil, Luca Fabris, et al.
Journal of Hepatology (2022) Vol. 78, Iss. 1, pp. 217-228
Closed Access | Times Cited: 41
Plasmon‐Enhanced Single Extracellular Vesicle Analysis for Cholangiocarcinoma Diagnosis
Mi Ho Jeong, Taehwang Son, Yoo Keung Tae, et al.
Advanced Science (2023) Vol. 10, Iss. 8
Open Access | Times Cited: 29
New Challenges in the Management of Cholangiocarcinoma: The Role of Liver Transplantation, Locoregional Therapies, and Systemic Therapy
Ezequiel Mauro, Joana Ferrer, Tamara Saurí, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1244-1244
Open Access | Times Cited: 25
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance
Diego F. Calvisi, Luke Boulter, Javier Vaquero, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 7, pp. 462-480
Open Access | Times Cited: 23
TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma
Jiong-Jie Yu, Sunbin Ling, Jiachen Hong, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 11, pp. e007479-e007479
Open Access | Times Cited: 23
Advances in targeted therapy of cholangiocarcinoma
Yuhang Li, Jianfeng Yu, Yujing Zhang, et al.
Annals of Medicine (2024) Vol. 56, Iss. 1
Open Access | Times Cited: 13
The correlation between LAG-3 expression and the efficacy of chemoimmunotherapy in advanced biliary tract cancer
Cheng‐Yu Tang, Yi‐Ting Lin, Yi‐Chen Yeh, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 2
Open Access | Times Cited: 1
Tumor-associated macrophages in cholangiocarcinoma: complex interplay and potential therapeutic target
Menghua Zhou, Chaoqun Wang, Shounan Lu, et al.
EBioMedicine (2021) Vol. 67, pp. 103375-103375
Open Access | Times Cited: 53
Regorafenib–avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial
Sophie Cousin, Coralie Cantarel, Jean‐Philippe Guégan, et al.
European Journal of Cancer (2022) Vol. 162, pp. 161-169
Closed Access | Times Cited: 35
Page 1 - Next Page

Scroll to top